Recently, the need for more standardized operation
Historic background of the model
Experimental liver fibrosis in mice can be induced by surgical intervention (e.g. bile duct ligation), genetic manipulation of fibrosis-related genes (e.g. Mdr2 knockout mice) or application of hepatotoxins. 1 In particular, the single or repeated administration of carbon tetrachloride (CCl 4 ) has become one of the most commonly used experimental models for inducing toxin-mediated liver fibrosis. However, almost all laboratory use protocols, which might vary with respect to usage of anaesthesia, hepatotoxin preparation, doses, treatment duration, administration routes, or the many other factors that may affect the outcome of experimentation. In the European Union, the laws on the protection of animals used for scientific purposes have recently changed dramatically by the implementation of the new EU Directive 2010/63 that contains 66 restrictive articles. 1 These require that, wherever possible, alternative scientific methods that do not need the use of live animals, should be applied in experimental research. The immediate implementation of the new EU Directive should foster the 3R (replacement, refinement, and reduction) principle that was proposed by William M S Russell and Rex L Burch in 1959 for the more ethical use of animals in testing. 2 To achieve this challenging objective, it is obvious that researchers in the field that use particular models must ensure that they work according to strict general guidelines and accepted standard operating procedures (SOPs). Therefore, we present here a detailed protocol that induces hepatic fibrosis in a highly reproducible manner. In addition, we discuss the historical background to that model and the pathobiochemical mechanisms that contribute to the formation of hepatic insult.
CCl 4 is widely used as a solvent for dissolving non-polar compounds, such as fats and oils. The acute toxicity of CCl 4 is well established from many animal studies. In particular, studies performed on rats have shown that the lethal dose (LD) 50 after acute oral uptake is in the range of 4.7-14.7 mL/kg body weight, depending on nutritional conditions and supplements administered. 3, 4 Single oral doses of CCl 4 in corn oil induce increased liver weight, elevated levels of fat, serum urea, liver enzyme activities, and clear histopathological evidence of liver damage with single cell necrosis; 5 whereas the long-term oral exposure to CCl 4 causes marked hepatotoxicity with resulting fibrosis, bile duct proliferation, cirrhosis and even hepatocellular carcinoma (HCC). 6 Toxicity of CCl 4 has three or four distinct phases. 7 The first two or three weeks are mainly characterized by necrosis indicated by rising activities of liver specific enzymes and decreasing values of pseudocholinesterase. During the next two or three weeks massive hepatic fat accumulation occurs and serum levels of triglycerides and aspartate aminotransferase (AST) are significantly increased, while hepatic function is reduced. During the third phase, the increase of AST continues, elevated levels of hydroxyproline and triglycerides are found, and overall liver function further decreases. In the final phase, the values of pseudocholinesterase further decrease, and atrophy of the liver is observed. 7 This may be combined with a significant decrease of serum albumin and weight loss which indicates progressive loss of hepatic function during prolonged fibrogenesis.
Pathogenic mechanisms of liver damage
CCl 4 is metabolized in the liver by the cytochrome P450 superfamily of monooxygenases (CYP family) to the trichloromethyl radical (CCl Ã 3 ). Subsequently, this radical reacts with nucleic acids, proteins, and lipids, thereby impairing key cellular processes resulting in altered lipid metabolism (fatty degeneration and steatosis) and lowered protein quantities ( Figure 1 ). Adduct formation between CCl Ã 3 and DNA further triggers mutations and the formation of HCC. The formation of trichloromethylperoxy radicals (CCl 3 OO*) resulting from oxygenation of CCl Ã 3 further initiates lipid peroxidation and the destruction of polyunsaturated fatty acids. Consequently, the membrane permeability in all cellular compartments (mitochondria, endoplasmic reticulum, and plasma membrane) is lowered and generalized hepatic damage occurs that is characterized by inflammation, fibrosis, cirrhosis and HCC. A comprehensive summary of the pathogenetic events that occur Figure 1 . Pathobiochemical sequence of events during carbon tetrachloride (CCl 4 )-induced liver damage. In the liver, CCl 4 is metabolized by cytochrome P450 (CYP) enzymes to a trichloromethyl radical that can be further oxygenated to the trichloromethylperoxy radical. Both radicals are highly reactive and induce complex cellular alterations that result in hepatotoxic damage, inflammation, fibrosis, cirrhosis and hepatocellular carcinoma (HCC).
in the liver during CCl 4 -induced damage is given elsewhere. 8 Besides its strong hepatotoxic effects, minor acute systemic toxicity of CCl 4 has been described decades ago, especially for the peritoneum, mucosa, respiratory tract and central nervous system. 9
Experimental procedure
General considerations Genetic background. It is well accepted that the susceptibility towards CCl 4 in mice is strongly straindependent (Table 1 ). In particular, BALB/c inbred mice are most sensitive to fibrosis induction, whereas FVB/N mice respond poorly to CCl 4 . Although C57BL/6 inbred mice develop only intermediate liver fibrosis, this strain is frequently used for fibrosis studies in the CCl 4 model because of the ready availability of genetically-modified mice.
Duration and intervals of treatment. Different responses to CCl 4 due to genetic reasons and severity (strength) of fibrogenesis can basically be modulated by application intervals and duration of treatment. In our experiments, intraperitoneal (IP) application of CCl 4 in C57BL/6 inbred mice twice a week for six weeks, or alternatively application three times a week for four weeks, results in fulminant deposition of intrahepatic collagen matrix and fibrosis resembling human stage 3 according to Desmet-Scheuer scoring. 10 In highly susceptible strains, four weeks of CCl 4 application is usually sufficient for fibrosis induction, while in fibrosis-resistant strains the poor susceptibility can in part be compensated for by prolonged treatment of up to 12 weeks.
Application routes. In principle, CCl 4 can be administered through IP injection, inhalation and gavage. The majority of investigators prefer IP application in mice for reasons of excellent reproducibility, good survival rates, 11 ease of performance, and safety. However, for specific aims (such as the induction of portal hypertension) or when the CCl 4 intoxication is established within the laboratory in rats, application via inhalation might be more appropriate, but requires a specific extraction hood in the laboratory and expertise (Figure 2 ). Only a few authors prefer administration of CCl 4 via gavage; however, in our opinion, this application route is not to be recommended due to frequent early mortality. 12 Biometric calculation of requested cohorts (IP treatment and inhalation). In a typical CCl 4 experiment one aims to compare fibrosis susceptibility of wildtype mice with a pharmacologically-treated or genetically-modified strain. Suitable readouts for ongoing hepatic fibrogenesis are, for instance, hepatic determination of hydroxyproline, measurement of alphasmooth muscle actin (a-SMA) or collagen type 1a1 (Col1) gene expression. 13 Regarding Col1 expression, our data (Figures 3a-3c ) typically reveal a variance of approximately 25% in each group. [14] [15] [16] In addition, we define a difference of 30% in Col1 mRNA expression to be biologically relevant. From these parameters the calculated effect size d is 1.44, as determined with the G Power V.3.1.5 software (that can be downloaded from the Heinrich Heine University, Du¨sseldorf, Germany, http://www.gpower.hhu.de/ en.html). 17 To achieve a statistical power of 80% and a specific a error probability of 0.05 the minimal required sample size in each group is n ¼ 9 mice (see Table 2 and Figure 3d ).
Practical implementation
(a) Intraperitoneal. In general, handling mice (i.e. taking them out of the cage, fixation, and exposition to a foreign surrounding) is already stressful for the animals. CCl 4 vapours should be considered to be toxic for humans. Thus prevention of accidental research personnel intoxication is crucial. The level of exposure should be minimized by handling CCl 4 in an appropriate location such as a fume hood. Protective clothing including a long sleeved laboratory coat, rubber gloves, safety goggles and a face mask are minimum standards that should avoid exposure over the recommended threshold limits. After application of CCl 4 , the operators should wash their hands thoroughly. In addition, the novel European animal welfare rules require that only trained laboratory personnel should perform the application of CCl 4 , ensuring swift and short animal handling times. The actual procedures are as follows:
1. Mice should be weighed and examined for signs of distress (i.e. changes in respiration, rough hair coat, unusual behaviour, hunched posture). Animals showing these abnormalities should be excluded from the study. 2. CCl 4 concentrations usually are 0.5 to 0.7 mL/g body weight diluted in corn oil. [18] [19] [20] Acute intoxication models with CCl 4 usually use higher doses (0.8-2 mL/g body weight) but mice should be sacrificed after 1 to 3 days. 21, 22 Please note that the injection solutions (CCl 4 or CCl 4 /corn oil) should be at room temperature or close to body temperature. 3. The required volume of CCl 4 should be calculated.
For practical reasons, we recommend to always inject a constant volume of 50 mL containing a solution of CCl 4 (e.g. Sigma-Aldrich, St Louis, MO, USA) in corn oil (e.g. Sigma-Aldrich). Accordingly, the required volume of CCl 4 (0.5-0.7 mL/g mouse weight is made up to 50 mL of total volume with corn oil. As an example, one would inject 10 mL CCl 4 dissolved in 40 mL of corn oil into a mouse that weighs 20 g to obtain a final dosage of 0. 
Animal burden/side-effects
Usually mice that receive IP injections of CCl 4 do not develop severe long-term complications. Although CCl 4 intoxication is intended to cause elevated liver enzymes and long-term complications such as portal hypertension, oesophageal bleeding and ascites leading to acute liver injury or liver fibrosis, this condition is usually not associated with pain in humans and thus most likely also not in mice. However, IP CCl 4 application is clearly associated with abdominal adhesions and hepatic inflammation and transient spasms.
(b) Inhalation. Inhalative intoxication with CCl 4 was first used extensively in rats, and was later transferred to mice. 23 Mice in the inhalation group might be treated with protocols that differ in inhalation time or intervals (commonly twice or three times per week) that either lead to significant fibrosis within four weeks 16 or might progress to liver cirrhosis with low serum sodium levels, ascites and portal hypertension after 11-15 weeks of treatment. Under the most damaging conditions, mortality rates can be as high as 70%, while short-cycle thrice-weekly inhalation usually results in significantly lower death rates (0-10%). Studies using inhalative CCl 4 usually aim towards the development of endstage liver cirrhosis with portal hypertension and are performed for 11-15 weeks. The drawback of this technique is that special equipment and expertise are required to avoid inhalative CCl 4 contamination of research personnel because CCl 4 vapours are considered to be toxic for humans. Thus, prevention of accidental intoxication is crucial (e.g. usage of latexfree gloves is important), and only trained laboratory personnel should perform the experiments. Every contact must occur, and every potentially contaminated subject must be placed under, the extraction hood.
The actual procedures that we favour in our experimentation are as follows: Mice should then be treated with one cycle/treatment in the initial three weeks, then two cycles/treatment in the fourth week, and three cycles/treatment thereafter.
Previously treatment consisted of two or more cycles, and these were separated by 2 min of breathing in ambient air not containing CCl 4 . 4. After treatment, the cage should be left in the extraction hood for another 10 min before it is removed. 5. When a mouse develops ascites, the inhalation should be stopped since ascites is a definitive sign of portal hypertension. The animals should have reached the stage of liver cirrhosis with portal hypertension and at this point the experiments should be conducted (e.g. efficacy analysis of antihypertensive drugs) or the animals should be sacrificed for further analysis (e.g. gene and protein expression in cirrhotic livers).
Prolonged inhalative CCl 4 treatment promotes severe cirrhotic changes in the liver with significant development of ascites 23 and more ascites than IP-treated animals. Therefore, mice subjected to inhalative CCl 4 treatment suffer from the complications of liver cirrhosis, show loss in body weight and less food intake, and are more fatigued, but do not experience pain or mutilations.
(c) Gavage. Our consortium does not recommend the regular application of CCl 4 by gavage due to high rates of early mortality 11 and additional burdens as specified below. Increased mortality would require higher sample numbers, which is not compatible with the 3R principle. 2 However, if the experimental set-up requires gavage application, investigators should refer to detailed protocols published elsewhere. 24, 25 Animal burden/side-effects CCl 4 oral feeding causes significant distress to the animal and CCl 4 is likely to cause chemically-induced inflammation in the intestinal mucosa. Intubation and application of CCl 4 /oil into the trachea needs to be avoided, as accidental CCl 4 application into the lung is usually instantly fatal for the mouse. Working Group on severity classification of scientific procedures performed on animals. These classification criteria can be found at: http://ec.europa.eu/environment/chemicals/lab_animals/pdf/report_ewg.pdf. The IP application twice a week of CCl 4 up to four weeks with no major impairment of liver function should be classified as a moderate procedure according to Article 15 of the above-mentioned EU Directive 2010/63.
Classification of severity of procedure
Prolonged inhalative CCl 4 treatment promotes severe cirrhotic changes in the liver with significant development of ascites 23 and more ascites than IP-treated animals. Therefore, mice subjected to inhalative CCl 4 treatment suffer from the complications of liver cirrhosis, show loss in body weight and less food intake, and are more fatigued. Because of the high mortality rate the procedure is classified as moderate to severe. In line with the 3R principle, the procedure should undergo a refinement, and humane endpoints (such as lethargy, reduced escape reflexes, reduced food intake, extensive body weight loss >20%, continuous spasm or others) must be implemented with frequent observation points to restrict pain, suffering, distress or lasting harm to the animals. Then the procedure can be reclassified as moderate.
Concluding remarks
Application of CCl 4 is a key model in experimental liver research that has been applied worldwide in more than 50,000 studies so far. The model is robust and leads to highly reproducible results. In our opinion, the best treatment route is the application via IP injection. With this SOP we aim to suggest technical and biometric standards facilitating reproducible animal experimentation in line with the new European animal welfare regulations.
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